Status:
COMPLETED
Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Airway Obstruction
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate the pharmacodynamics of single doses of AZD3199 in asthmatic patients.
Eligibility Criteria
Inclusion
- Asthmatic patients with pre-bronchodilatory FEV1 above 60% of predicted normal and above 1.5 liters.
- Men and post-menopausal women above 18 years of age.
- Reversible airway obstruction in response to classical beta2-agonist (salbutamol)
- Non/ex-smokers
Exclusion
- Any clinically significant disease or disorder other than asthma
- Any clinically relevant abnormal findings at screening examinations
- Treatment with systemic glucocorticosteroids within the past 30 days
- Inhaled corticosteroid use if dosing is not kept constant
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00736489
Start Date
August 1 2008
End Date
December 1 2008
Last Update
May 19 2014
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Hvidovre, Denmark
2
Research Site
Gothenburg, Sweden
3
Research Site
Luleå, Sweden
4
Research Site
Lund, Sweden